innerva pharmaceuticals
Ophthalmology & Eye Clinics · Biotechnology
Overview
Innerva Pharmaceuticals is an innovative ophthalmic startup developing novel therapies for ocular surface pain.
Key facts
These are the key facts about innerva pharmaceuticals on Alion as of Nov 13, 2026. innerva pharmaceuticals is headquartered in Barcelona, Spain. The latest round is Venture - Series Unknown of $2.3M, announced in 2024.
- Headquarters
- Barcelona, SpainAlion company profile, updated Oct 11, 2026
- Employees
- 1-10Alion company profile, an estimated range
- Total raised
- $2.3MSum of 1 equity round Alion knows
- Latest round
- Venture - Series Unknown · $2.3M · Feb 29, 2024Press report · innervapharma.com
Funding and backers
Total raised
$2.3M
1 round on record
Latest round
$2.3M
Venture round · Feb 2024 · 2 yr ago
Team
1-10
employees, estimated range
Backers
1
Inveready
The money's age
Long since its last round
32 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 29, 2024
Raised a round Venture round $2.3M · led by Inveready
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2024 | $2.3M | Inveready lead | innervapharma.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Inveready Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Home About us Our research About us Our vision: To establish ocular hydration as a new standard in preventive healthcare, unlocking earlier…
Advanced Retinal Imagingfor Better Patient Outcomes. RetinalGenix Technologies delivers cutting-edge ophthalmic diagnostic solutions…
Accelerating Next Generation Therapies for Ophthalmology. About Us.
Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom…
NATURAL THERAPY FOR OCULAR SURFACE DISEASE. TearSolutions has developed LacripepTM, a proprietary first-in-class peptide therapy.
VisusNano is a biotechnology start-up company developing a drug-eluting intraocular lens, which has the potential to revolutionise cataract…
Financials
Total raised
$2.3M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $2.3M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Innerva Pharmaceuticals closes 2.3 million Euro round led by Inveready
Innerva Pharmaceuticals closes 2.3 million Euro round led by Inveready to develop a First in Class drug candidate for ocular surface pain. The same entrepreneur/investor tandem intends to replicate their success withAvizorex Pharma ("AVX Pharma"), acquire
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Barcelona
Spain
HQ
Let's get in touch
1-10 est. staff
08028 Barcelona, Spain
How to cite this page
Alion, "innerva pharmaceuticals: key facts", as of Nov 13, 2026. https://alion.io/company/innervapharma
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0